Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 176,604 shares of the pharmaceutical company’s stock after selling 9,867 shares during the period. Skandinaviska Enskilda Banken AB publ owned about 0.07% of Vertex Pharmaceuticals worth $78,647,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Virtus Investment Advisers LLC lifted its position in shares of Vertex Pharmaceuticals by 25.0% during the 2nd quarter. Virtus Investment Advisers LLC now owns 966 shares of the pharmaceutical company’s stock valued at $430,000 after acquiring an additional 193 shares during the period. Norges Bank purchased a new position in Vertex Pharmaceuticals in the 2nd quarter valued at approximately $1,593,974,000. Quadrature Capital Ltd acquired a new position in Vertex Pharmaceuticals during the second quarter worth $7,974,000. Scotia Capital Inc. raised its holdings in Vertex Pharmaceuticals by 6.8% during the second quarter. Scotia Capital Inc. now owns 6,484 shares of the pharmaceutical company’s stock worth $2,886,000 after purchasing an additional 412 shares during the last quarter. Finally, Groupama Asset Managment boosted its position in Vertex Pharmaceuticals by 18.0% during the second quarter. Groupama Asset Managment now owns 61,297 shares of the pharmaceutical company’s stock worth $27,050,000 after purchasing an additional 9,364 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VRTX has been the subject of a number of research analyst reports. Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 5th. Evercore ISI dropped their target price on shares of Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a report on Thursday, September 11th. Wall Street Zen downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 22nd. Scotiabank initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $495.00 price target on the stock. Finally, Canaccord Genuity Group dropped their price objective on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $491.95.

Insider Transactions at Vertex Pharmaceuticals

In related news, Chairman Jeffrey M. Leiden sold 53,604 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $440.72, for a total value of $23,624,354.88. Following the completion of the sale, the chairman directly owned 24,026 shares in the company, valued at approximately $10,588,738.72. The trade was a 69.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.5%

Vertex Pharmaceuticals stock opened at $432.17 on Friday. The stock has a fifty day moving average price of $414.58 and a 200 day moving average price of $425.09. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.68. The firm has a market capitalization of $109.65 billion, a P/E ratio of 30.89 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same quarter in the previous year, the business earned $4.38 EPS. The firm’s revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.